Diabetes Clinical Paper Summaries
DELIVER-T Study Insights
This article reviews real-world findings from the DELIVER-T study regarding the intensification of treatment with Toujeo® in adults receiving tirzepatide. Explore the data on glycaemic control and safety to understand the role of basal insulin in this patient population.
Author: Sanofi Editorial Team
Research Review Educational Series
Management of Type 2 Diabetes: Guideline Perspectives and Clinical Evidence for Basal Insulin.
MAT-AU-2301722 - 2.0 - 07/2026
Waddling-Gait---Robert,-28-year-old-mild-LOPD-patient
Waddling Gait - Robert, 28-year-old mild LOPD patient
Reaching-Overhead---Robert,-28-year-old-mild-LOPD-patient
Reaching Overhead - Robert, 28-year-old mild LOPD patient
Standing-From-Sitting---Robert,-28-year-old-mild-LOPD-patient
Standing From Sitting - Robert, 28-year-old mild LOPD patient
Climbing-Stairs---Robert,-28-year-old-mild-LOPD-patient
Climbing Stairs - Robert, 28-year-old mild LOPD patient
Waddling-Gait---Karen,-18-year-old-moderate-LOPD-patient
Waddling Gait - Karen, 18-year-old moderate LOPD patient
Reaching-Overhead---Karen,-18-year-old-moderate-LOPD-patient
Reaching Overhead - Karen, 18-year-old moderate LOPD patient
Standing-From-Sitting---Karen,-18-year-old-moderate-LOPD-patient
Standing From Sitting - Karen, 18-year-old moderate LOPD patient
Climbing-Stairs---Karen,-18-year-old-moderate-LOPD-patient
Climbing Stairs - Karen, 18-year-old moderate LOPD patient
ASPIRE-ICT-1-23_Harrington_MAT-AU-2302788-1
ASPIRE-ICT-1-23_Kyle-Blakey_MAT-AU-2302789-1
Which-biologic-and-why--When-to-switch-to-another-one-
Waddling-Gait---Brian,-44-year-old-severe-LOPD-patient
Waddling Gait - Brian, 44-year-old severe LOPD patient
Reaching-Overhead---Brian,-44-year-old-severe-LOPD-patient
Reaching Overhead - Brian, 44-year-old severe LOPD patient
Standing-From-Sitting---Brian,-44-year-old-severe-LOPD-patient
Standing From Sitting - Brian, 44-year-old severe LOPD patient
Climbing-Stairs---Brian,-44-year-old-severe-LOPD-patient
Climbing Stairs - Brian, 44-year-old severe LOPD patient
RESP-ICT2_Wark_MAT-AU-2301970
.webp/jcr:content/RESP-ICT2-Wark_400X300%20(1).webp)
RESP-ICT2_Wark_MAT-AU-2301970
RESP-ICT2_Stone_MAT-AU-2301972
.webp/jcr:content/RESP-ICT2-Stone_400X300%20(1).webp)
RESP-ICT2_Stone_MAT-AU-2301972
Remission-in-rheumatology---Dr-Michelle-Tellus
.webp/jcr:content/RESP-ICT2-Tellus_400X300%20(1).webp)
Remission in rheumatology - Dr Michelle Tellus
Pavord_MAT-AU-2300571
Pavord_MAT-AU-2300571
Wark_MAT-AU-2300572
Wark_MAT-AU-2300572
Q-A-Discussion_MAT-AU-2300573
Q&A-Discussion_MAT-AU-2300573
RESP-ICT3_Tellus_MAT-AU-2302033
RESP-ICT3_Tellus_MAT-AU-2302033
RESP-ICT3_Lee_MAT-AU-2302034
RESP-ICT3_Lee_MAT-AU-2302034
RESP-ICT3_Hew_MAT-AU-2302035
RESP-ICT3_Hew_MAT-AU-2302035
Reduced-need-for-sinus-surgery
Up-to-45--of-severe-asthma-patients-have-comorbid-CRSwNP
Severe-asthma-with-comorbid-CRSwNP-leads-to-more-severe-disease
.2024-06-04-09-20-31.png)
Less-rescue-oral-corticosteriod-use
Improved-sense-of-smell
Reduced-obstruction-and-congestion
Reduced-asthma-exacerbations-and-improved-lung-function
IL-4-and-IL-13-are-key-and-central-drivers-of-type-2-inflammation
Gaucher-diagnosis-1
RESP-ICT2_Debate_MAT-AU-2301973
RESP-ICT2_Debate_MAT-AU-2301973
RESP-ICT3_Q-A_MAT-AU-2302036
RESP-ICT3_Q&A_MAT-AU-2302036
ASPIRE-ICT1-23_Q-A_MAT-AU-2302791-1
RESP-ICT2_Stone_CS_MAT-AU-2301975
RESP-ICT2_Stone_CS_MAT-AU-2301975
RESP-ICT2_Wark_CS_MAT-AU-2301974
RESP-ICT2_Wark_CS_MAT-AU-2301974
RESP-ICT2_Panel-Discussion_MAT-AU-2301976
RESP-ICT2_Panel-Discussion_MAT-AU-2301976
SANA7993_Safety-Page-Tables_V0.2_1_New3
Products_Dermatology_Atopic-Dermatitis_Adverse-Events-Adults_18012021
Le-Cercle---Dr-Christophe-LEFEZ
